Login
Home / KHTRF : OTC
Follow Compare
AI Analysis Fundamentals Valuation Video Analysis News Similar
Quarterly Quarterly (TTM) Annually

AI Analysis

Log in to generate an AI summary for this stock.

Log in to generate a MOAT report for this stock.

Log in to generate an earnings report for this stock.

Log in to generate an operating leverage report for this stock.

Log in to generate a management report for this stock.

Log in to generate a valuation report for this stock.

Knight Therapeutics Inc.

$7.15 +$2.80 (+64.37%)
OTC · 11 Sep 2026 20:00 UTC
Previous Close
$7.15
Day Range
$7.15$7.24
Year Range
$4.07$7.4
Market Cap
701.98M
AVG Volume
5.68K
Trailing/Forward PE
66.96/26.17
PEG ratio
0.73
Dividend Yield
-
Next Earnings Date
2026-11-05
Primary Exchange
Other OTCUS
Revenue (CAD)
050M100M150M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
Net Income (CAD)
-20M-10M010M20M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
Operating Income (CAD)
-10M-5M05M10M15M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
EBITDA (CAD)
-10M010M20M30M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
Cash Flows (CAD)
-20M020M40M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
EPS (CAD)
-0.2-0.100.10.224 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
Expenses (CAD)
020M40M60M80MR&DSG&ACapex24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
Cash & Debt (CAD)
050M100M150M200MCashLong Term DebtShort Term Debt24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
Debt ratios
-4-20224 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
Margins
0%20%40%60%24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
Return on Capital
-2%-1%0%1%2%24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
Shares Outstanding
050M100M150M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
Book Value Per Share (CAD)
02.557.51024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
Total Assets (CAD)
0500M1B1.5B24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
PE Ratio
0500100015002000med 47.79Sep 21Dec 21Apr 22May 25Aug 25Nov 25Sep 26
Free Cash Flow Yield
-5%0%5%10%med 0.96%Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
Price to Sales
1.21.41.61.822.2med 1.59Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
EV/EBITDA
5101520med 11.33Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
Price/Operating Cashflow
020406080med 15.12Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
Price to Book
0.60.811.21.4med 0.77Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
Knight Therapeutics Inc.
KHTRF
Stockpicker

Video analysis: KHTRF

All videos

No video analysis for this stock yet. Request one from our team.

Your email is used only to follow up on this request. We do not add you to marketing lists. Privacy Policy

News: KHTRF

Knight Therapeutics Q2 Earnings Call Highlights

marketbeat.com · 9 Aug 2026

Knight Therapeutics Q2 Earnings Call Highlights

Knight Therapeutics TSE: GUD reported record results for the first six months of 2026 and raised its full-year outlook, citing growth in its promoted products, contributions from recent launches and favorable foreign-exchange effects.
Knight Therapeutics Announces Repayment of Revolving Credit Facility

globenewswire.com · 17 Jun 2026

Knight Therapeutics Announces Repayment of Revolving Credit Facility

MONTREAL, June 17, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (“Knight”) (TSX: GUD), a pan-American (ex-US) pharmaceutical company, announced today that it has repaid all amounts outstanding under its revolving credit facility with National Bank of Canada and a syndicate of lenders.

Similar companies

Disclaimer: The historical data presented on this platform is provided by Financial Modeling Prep. Stock Picker is a platform for informational purposes only and does not provide financial advice. Users are encouraged to conduct their own research and consult with a qualified financial advisor before making investment decisions.